Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Acquisitions: -$1,109M in Q3 2026, down 111,000.0% from a year earlier.
Latest, Q3 2026
-1,109
Period ended Sep 30, 2026
Change on a year earlier
-111,000.0%
1 in Q3 2025
History
9 quarters
Since Q3 2024
Sources
5
Documents cited below
Where the Q3 2026 figure comes from
“|| Acquisitions of businesses | 6.3 | – 1 109 | 1”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Postgres DB + Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquisitions ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | -1,109 | -111,000.0% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | -23 | -81.9% | Novartis 6-K (0001114448-26-000012, filed 2026-07-21) ↗ |
| Q1 2026 | Mar 31, 2026 | 6.30 | -100.1% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | -21 | -95.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 1 | -101.7% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2025 | Jun 30, 2025 | -127 | – | Novartis 6-K (0001114448-26-000012, filed 2026-07-21) ↗ |
| Q1 2025 | Mar 31, 2025 | -12,041 | – | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | -426 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | -58 | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
Cite this data
StockData. (2026). Novartis Acquisitions ($M), quarterly Q3 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-cf-acquisitions
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.